Compare PCTY & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCTY | LNTH |
|---|---|---|
| Founded | 1997 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 6.6B |
| IPO Year | 2014 | 2014 |
| Metric | PCTY | LNTH |
|---|---|---|
| Price | $146.92 | $100.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 6 |
| Target Price | ★ $176.59 | $87.00 |
| AVG Volume (30 Days) | 460.1K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.39 | N/A |
| EPS | ★ 4.92 | 2.91 |
| Revenue | ★ $1,771,326,000.00 | $343,374,000.00 |
| Revenue This Year | $11.52 | N/A |
| Revenue Next Year | $7.98 | $14.19 |
| P/E Ratio | ★ $28.93 | $34.48 |
| Revenue Growth | ★ 11.04 | 3.62 |
| 52 Week Low | $92.99 | $49.67 |
| 52 Week High | $169.09 | $111.86 |
| Indicator | PCTY | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 43.86 |
| Support Level | $141.00 | $99.80 |
| Resistance Level | $148.70 | $101.43 |
| Average True Range (ATR) | 4.41 | 0.49 |
| MACD | -2.15 | 0.06 |
| Stochastic Oscillator | 35.19 | 12.94 |
Paylocity is a cloud-based human capital management provider offering payroll, compliance, and human resources management solutions. With the addition of expense and IT management modules, Paylocity unifies back-office operations spanning HR, finance, and IT on a single platform and bills customers on a subscription basis. The firm's customer base skews toward the midmarket and is primarily based in the US. As of fiscal 2026, Paylocity has nearly 44,400 customers.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.